Combining BET and HDAC inhibitors synergistically induces apoptosis of melanoma and suppresses AKT and YAP signaling
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
// Anja Heinemann 1, 2, 3 , Carleen Cullinane 4 , Ricardo De Paoli-Iseppi 2, 5 , James S. Wilmott 2, 5 , Dilini Gunatilake 1, 2, 3 , Jason Madore 2, 5 , Dario Strbenac 6 , Jean Y. Yang 6 , Kavitha Gowrishankar 1, 2 , Jessamy C. Tiffen 1, 2, 3 , Rab K. Prinjha 7 , Nicholas Smithers 7 , Grant A. McArthur 4 , Peter Hersey 1, 2, 3 , Stuart J. Gallagher 1, 2, 3 1 Melanoma Research Group, Kolling Institute of Medical Research, University of Sydney, St Leonards NSW, Australia 2 Melanoma Institute of Australia, North Sydney, NSW, Australia 3 Melanoma Immunology and Oncology Group, Centenary Institute, University of Sydney, Camperdown, NSW, Australia 4 Translational Research Laboratory, Peter MacCallum Cancer Centre, Melbourne, VIC, Australia 5 Sydney Medical School, University of Sydney, Sydney, NSW, Australia 6 School of Mathematics and Statistics, University of Sydney, Sydney NSW, Australia 7 Epinova Discovery Performance Unit, GlaxoSmithKline, Stevenage, United Kingdom Correspondence to: Stuart J. Gallagher, e-mail: stuart.gallagher@sydney.edu.au Keywords: panobinostat, I-BET151, melanoma, bromodomain, epigenetic Received: February 17, 2015 Accepted: May 23, 2015 Published: June 05, 2015 ABSTRACT Histone acetylation marks have an important role in controlling gene expression and are removed by histone deacetylases (HDACs). These marks are read by bromodomain and extra-terminal (BET) proteins and novel inhibitiors of these proteins are currently in clinical development. Inhibitors of HDAC and BET proteins have individually been shown to cause apoptosis and reduce growth of melanoma cells. Here we show that combining the HDAC inhibitor LBH589 and BET inhibitor I-BET151 synergistically induce apoptosis of melanoma cells but not of melanocytes. Induction of apoptosis proceeded through the mitochondrial pathway, was caspase dependent and involved upregulation of the BH3 pro-apoptotic protein BIM. Analysis of signal pathways in melanoma cell lines resistant to BRAF inhibitors revealed that treatment with the combination strongly downregulated anti-apoptotic proteins and proteins in the AKT and Hippo/YAP signaling pathways. Xenograft studies showed that the combination of inhibitors was more effective than single drug treatment and confirmed upregulation of BIM and downregulation of XIAP as seen in vitro . These results support the combination of these two classes of epigenetic regulators in treatment of melanoma including those resistant to BRAF inhibitors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“Synergy of drug interactions was calculated using the fixed ratio/combination index method [42].”
MethodSuper-enhancers in the control of cell identity and disease
Hnisz, D., Abraham, B. J., Lee, T. I., Lau, A., Saint-André, V., Sigova, A. A., Hoke, H. A., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.09.053 · Cited by 3,662 · cited 1×
“BET proteins on the other hand are components of complexes that target transcription factors to acetylated histones particularly at sites of so called super enhancers [20, 21].”
BackgroundCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Selective Inhibition of Tumor Oncogenes by Disruption of Super-Enhancers
Lovén, J., Hoke, H. A., Lin, C. Y., Lau, A., Orlando, D. A., Vakoc, C. R., Bradner, J. E., Lee, T. I., & Young, R. A. (2013) · Cell · doi:10.1016/j.cell.2013.03.036 · Cited by 2,961 · cited 1×
“BET proteins on the other hand are components of complexes that target transcription factors to acetylated histones particularly at sites of so called super enhancers [20, 21].”
BackgroundA landscape of driver mutations in melanoma
Hodis, E., Watson, I. R., Kryukov, G. V., Arold, S. T., Imielinski, M., Theurillat, J.-P., Nickerson, E., Auclair, D., Li, L., Place, C., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.024 · Cited by 2,610 · cited 1×
“Dysregulation of chromatin structure is a frequent event in melanoma [1–3] and underlies many aspects of melanoma biology including resistance to targeted therapies [4, 5] and melanoma invasiveness [6].”
BackgroundEpigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
Bali, P., Pranpat, M., Bradner, J., Balasis, M., Fiskus, W., Guo, F., Rocha, K., Kumaraswamy, S., Boyapalle, S., Atadja, P., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.c500186200 · Cited by 755
Ram, O., Goren, A., Amit, I., Shoresh, N., Yosef, N., Ernst, J., Kellis, M., Gymrek, M., Issner, R., Coyne, M., et al. (2011) · Cell · doi:10.1016/j.cell.2011.09.057 · Cited by 331
Place your BETs: the therapeutic potential of bromodomains
Prinjha, R. K., Witherington, J., & Lee, K. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.12.002 · Cited by 197 · cited 1×
“The bromodomains act to target protein complexes to particular chromosomal regions involved in gene transcription and act as coregulators of transcription [14–16].”
BackgroundSelf-citation
Cited by
Indole: A privileged scaffold for the design of anti-cancer agents
Wan, Y., Li, Y., Yan, C., Yan, M., & Tang, Z. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111691 · Cited by 516
BET Proteins as Targets for Anticancer Treatment
Stathis, A., & Bertoni, F. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0605 · Cited by 463
BET inhibitors: a novel epigenetic approach
Doroshow, D. B., Eder, J. P., & LoRusso, P. M. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx157 · Cited by 367
Polytherapy and Targeted Cancer Drug Resistance
Chatterjee, N., & Bivona, T. G. (2019) · Trends in Cancer · doi:10.1016/j.trecan.2019.02.003 · Cited by 270
Inhibition of histone deacetylases in melanoma—a perspective from bench to bedside
Hornig, E., Heppt, M. V., Graf, S. A., Ruzicka, T., & Berking, C. (2016) · Experimental Dermatology · doi:10.1111/exd.13089 · Cited by 50
Vitamin C Sensitizes Melanoma to BET Inhibitors
Mustafi, S., Camarena, V., Volmar, C.-H., Huff, T. C., Sant, D. W., Brothers, S. P., Liu, Z.-J., Wahlestedt, C., & Wang, G. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-2040 · Cited by 47
“BETi I-BET151 and Histone deacetylase (HDAC) inhibitor LBH589 synergistically promote apoptosis in melanoma cells (14).”
Background
Metadata
- Authors
- Heinemann, A., Cullinane, C., De Paoli-Iseppi, R., Wilmott, J. S., Gunatilake, D., Madore, J., Strbenac, D., Yang, J. Y., Gowrishankar, K., Tiffen, J. C., Prinjha, R. K., Smithers, N., McArthur, G. A., Hersey, P., & Gallagher, S. J.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2015-06-05
- Volume
- 6
- Issue
- 25
- Pages
- 21507-21521
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2168950900
- Cited by
- 82
- References
- 9
- FWCI
- 3.73
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.